OptiBiotix Health plc (AIM: OPTI), a life sciences company specialising in microbiome-based health products, announced on Wednesday that it has signed a distribution agreement with a well-known direct selling weight management company.
Under the deal, OptiBiotix will supply SlimBiome finished products under the distributor's branding, as well as a WellBiome product to be included in its portfolio. The distributor plans to launch first in its largest sales territory, followed by other European markets, with products available through both e-commerce and a long-established consultant network. An initial order is expected within three months, with the official launch anticipated in H1 2026.
The agreement highlights growing demand for functional ingredients that complement the surge of interest in anti-obesity drugs. OptiBiotix's products are positioned to add scientifically backed functionality to established weight management brands.
Founded in 2012, OptiBiotix develops microbiome modulators targeting obesity, cardiovascular health and diabetes. The company has signed over 20 agreements with international food and healthcare firms and continues to expand its consumer supplement portfolio.
Avant Technologies enters joint venture to advance stem cell-based diabetes treatments
Innovent and Ollin report progress in development of OLN324 (IBI324)
Alteogen secures European Commission approval for aflibercept biosimilar EYLUXVI
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Ascletis presents ASC30 study results at EASD Annual Meeting
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Novo Nordisk to streamline operations and reinvest in diabetes and obesity growth
NICE endorses AOTI's TWO2 therapy for diabetic foot ulcers
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
OptiBiotix signs distribution deal with major weight management company
GoodRx partners with Novo Nordisk to offer Ozempic and Wegovy at USD499 per month
Ocular Therapeutix secures FDA special protocol assessment for AXPAXLI NPDR trial